Msh Capital Advisors LLC Outlook Therapeutics, Inc. Transaction History

Msh Capital Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Feb 13, 2025	SELL	$0.34 - $11.94 $50,522 - $1.77 Million	-148,596 Closed	0 $0
Q4 2023 Feb 13, 2025	SELL	$0.22 - $0.66 $8,019 - $24,059	-36,454 Reduced 19.7%	148,596 $58.5 Million
Q3 2023 Feb 13, 2025	SELL	$0.2 - $1.78 $802 - $7,144	-4,014 Reduced 2.12%	185,050 $40.9 Million
Q2 2023 Feb 13, 2025	BUY	$1.02 - $1.89 $123,315 - $228,497	120,898 Added 177.36%	189,064 $329 Million
Q1 2023 Feb 13, 2025	BUY	$1.0 - $1.35 $68,166 - $92,024	68,166 New	68,166 $74.3 Million
Q2 2022 Feb 13, 2025	SELL	$0.91 - $2.01 $11,830 - $26,129	-13,000 Closed	0 $0
Q1 2022 Feb 13, 2025	BUY	$1.22 - $2.03 $15,860 - $26,389	13,000 New	13,000 $23.1 Million

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $423M
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Msh Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Msh Capital Advisors LLC with notifications on news.